Health Condition 1: N390- Urinary tract infection, site notspecified
Conditions
Interventions
Intervention1: Ciprofloxacin: Tablet Ciprofloxacin 500mg single dose
Control Intervention1: Placebo single dose: Placebo [Probiotic tablet: Streptococcus faecalis(30.0M), Clostridium Butyricum(2.0M),
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Consenting patients scheduled for rigid cystoscopy without any high-risk parameters requiring prophylactic/therapeutic antibiotic cover during the procedure.
Exclusion criteria
Exclusion criteria: Patient with any of the following high-risk parameters- Comorbidities- Diabetes mellitus, obesity(BMI more than 25),on immunosuppressive drugs, Prosthetic implant,History of cardiac valvular disease. Lower urinary tract specific history History of Genitourinary anomalies,Prior urological surgery,Recurrent UTI,Indwelling catheter,Neurogenic lower urinary tract dysfunction,elevated post void residual or bladder outlet obstruction. Current symptoms of UTI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients showing significant bacterial growth in the urine of test and control group.Timepoint: 0, 3 and 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidences of the treatment emergent adverse events (TEAE) related to the prophylactic single dose oral ciprofloxacinTimepoint: 0, 3 & 7 days;The proportion of patients showing symptoms of urosepsis by SIRS.Timepoint: 3 & 7 days;Categorization of the outcomes according to Clavien-Dindo classification.Timepoint: 3 & 7 days | — |
Countries
India
Contacts
Public ContactDR RAVI SHARMA
G.T.B. Hospital and University College of Medical Sciences, Delhi 110095
Outcome results
None listed